Getting Direct to patients is exactly what I mean but I believe no pharma is going to be able to just buy it with their cash on hand precisely because of the huge potential to radically change the treatment of many diseases and not just cancer. A joint venture to co-develop future treatments makes a good deal of sense. A buyout at well below a fairly discounted true future market value because folks don't understand the potential of Direct is not what I expect and that is what most of the discussion about share price on this board is reflective of. I believe there is a go between in place now between NWBO and Merck who will educate Merck and any other potential investors what they are investing in once he is given a look under the hood that doesn't reveal all the details but is detailed enough to convince others about it's true potential. I suspect he has a strong clue as to the details though and might just be saddling up with the folks he strongly feels has the future of cancer treatment in their hands and is ready to go along for the ride.
NWBO knows money is needed to rapidly expand commercialization for L and Direct. Cognate has significant backers but NWBO needs money to get approval and expansion of indications for L and approval for Direct in multiple indications. The sooner that money shows up in an equitable way the sooner all parties involved can become more equally motivated to move treatments to patients ASAP. Big pharma is making money on their checkpoint inhibitor products right now and they don't have any incentive to make less in a price restricted combo with L. If Direct can be proven to be able to blow right past them then someone is going to move sooner rather than later. Best wishes.
News 
Market Data 
Discover 
AI
